Home World News Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients... World News Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - July 8, 2025 777 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MIDAS study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR What to Expect During a Skin Cancer Screening May 31, 2022 EMA Recommends Extension of Indications for Dostarlimab January 23, 2025 ASCO Annual Meeting 2023: Trastuzumab Deruxtecan Effectively Treats HER2-Expressing Tumors and... June 5, 2023 Activity of Alectinib for ALK-Rearranged Metastatic Solid Tumours, Other Than NSCLC April 19, 2022 Load more HOT NEWS Amivantamab Plus Lazertinib Shows Superior Efficacy to Osimertinib in First-Line Treatment... EMA Recommends Extension of Indications for Datopotamab Deruxtecan Woman Dances Through Chemo Sessions, Emphasizes Importances of Being ‘Joyful’ 6 things you need to know about cervical screening
